The mission of the Georgetown Lombardi Comprehensive Cancer Center's (LCCC) Administration is to facilitate and implement LCCC's vision and create, support, and sustain an environment that fosters research, interactivity, and optimal productivity of Cancer Center investigators and adds value to the Center. Supporting 4 Research Programs, 9 Shared Resources and 91 members focused on basic, translational, clinical, and population-based research, Administration oversees $30M in grants and contracts (direct costs). Headed by Michael Vander Hoek, MHSA, Associate Director (AD) for Administration, the administrative team supports LCCC leadership planning, strategic investments, benchmarking and evaluation, and communication with constituencies. In addition to building an experienced management team to support Cancer Center members, Vander Hoek managed the recruitment of several key LCCC leaders including the Deputy Director, AD for Clinical Research, and the Codirector of the Biostatistics &Bioinformatics Shared Resource (SR) and supported the faculty appointments and promotions of several SR Directors and Research Program members. He and his team have successfully managed institutional commitments to support these strategic initiatives. Administration tracks and manages LCCC's $25M per year in institutional investments from the University and MedStar Health, ensuring investments are linked to LCCC's Strategic Plan. Administration documents and executes LCCC policies on membership, pilot funding, equipment purchases. Shared Resources and space. During this period. Administration supported opening a community office for health disparities research in one of the most underserved areas ofthe District of Columbia. Cancer research education and training are also coordinated by Administration. Significant expansion of administrative activities have supported an increasingly productive relationship with our MedStar Health clinical partner in strengthening a clinical network aimed at increasing accrual to therapeutic trials and increasing the diversity of individuals enrolling on trials. For example. Administration negotiated a research agreement to expand and strengthen the clinical research organizational structure across the Georgetown MedStar Cancer Network creating an integrated Clinical Research Management Office (ICRMO). Other activities are highlighted within the narrative. The CCSG budget requested represents 6.6% of the total LCCC administrative budget and represents 7.6% ofthe total CCSG budget.

Public Health Relevance

Lombardi Administration advances the vision of Cancer Center leaders in a thriving environment that supports, evaluates and sustains research activities that are innovative, transformative, collaborative and well organized.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
United States
Zip Code
Bae, Woo Kyun; Yoo, Kyung Hyun; Lee, Ji Shin et al. (2015) The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers. Mol Carcinog 54:1172-80
Adams, Inez; Christopher, Juleen; Williams, Karen Patricia et al. (2015) What Black Women Know and Want to Know About Counseling and Testing for BRCA1/2. J Cancer Educ 30:344-52
Butrick, Morgan; Kelly, Scott; Peshkin, Beth N et al. (2015) Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling. Genet Med 17:467-75
London, Laricca; Hurtado-de-Mendoza, Alejandra; Song, Minna et al. (2015) Motivators and barriers to Latinas' participation in clinical trials: the role of contextual factors. Contemp Clin Trials 40:74-80
Mays, Darren; Niaura, Raymond S; Evans, W Douglas et al. (2015) Cigarette packaging and health warnings: the impact of plain packaging and message framing on young smokers. Tob Control 24:e87-92
Zhi, Xiuling; Lin, Ling; Yang, Shaoxian et al. (2015) ?II-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology 61:598-612
Rush, Christina L; Darling, Margaret; Elliott, Maria Gloria et al. (2015) Engaging Latina cancer survivors, their caregivers, and community partners in a randomized controlled trial: Nueva Vida intervention. Qual Life Res 24:1107-18
Heckler, Mary Mazzotta; Riggins, Rebecca B (2015) ERR? splice variants differentially regulate cell cycle progression. Cell Cycle 14:31-45
Kim, B; Wang, S; Lee, J M et al. (2015) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:1083-93
Tong, Angie; Kelly, Scott; Nusbaum, Rachel et al. (2015) Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology 24:33-9

Showing the most recent 10 out of 544 publications